Veradermics, Inc Financing Cash Flow
Veradermics, Inc (MANE) reported Financing Cash Flow of $711.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-11
- Veradermics, Inc net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $442.70M, a 343076.74% increase year-over-year.
- Veradermics, Inc net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $269.11M, a 3094.98% increase year-over-year.
- Veradermics, Inc net cash provided by (used in) financing activities for the quarter ending 2025-06-30 was $129.00K.
- Veradermics, Inc net cash provided by (used in) financing activities for the quarter ending 2025-03-31 was $8.42M.
- Veradermics, Inc net cash provided by (used in) financing activities for fiscal 2025 was $159.14M, a 163.15% increase from fiscal 2024.
- Veradermics, Inc net cash provided by (used in) financing activities for fiscal 2024 was $60.48M.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|
| 2026-06-30 | $442.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $711.81M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $269.11M 10-Q · filed 2026-05-12 | ||
| 2025-12-31 | $159.14M 10-K · filed 2026-03-30 | ||
| 2025-06-30 | $129.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $8.55M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $8.42M 10-Q · filed 2026-05-12 | ||
| 2024-12-31 | $60.48M 10-K · filed 2026-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |